Current understanding of primary biliary cholangitis

키워드

참고문헌 (171)

1. Addison T, "On a certain affection of the skin-vitiligoideaalpha-plana, B-tuberosa", Guys Hosp Rep, 7, pp.265~276 (1851)
2. Dauphinee JA, "Primary biliary cirrhosis", Can Med Assoc J, 61, pp.1~6 (1949)
3. Beuers U, "Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’", Clin Res Hepatol Gastroenterol, 39, pp.e57~e59 (2015)
4. Beuers U, "Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’", Dig Liver Dis, 47, pp.924~926 (2015)
5. Beuers U, "Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’", Am J Gastroenterol, 110, pp.1536~1538 (2015)
6. Beuers U, "Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’", Clin Gastroenterol Hepatol, 13, pp.1867~1869 (2015)
7. Beuers U, "Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’", J Hepatol, 63, pp.1285~1287 (2015)
8. Beuers U, "Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’", Gastroenterology, 149, pp.1627~1629 (2015)
9. Beuers U, "Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’", Gut, 64, pp.1671~1672 (2015)
10. Beuers U, "Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’", Hepatology, 62, pp.1620~1622 (2015)
11. Tanaka A, "Autoimmune liver diseases in the Asia-Pacific region:proceedings of APASL symposium on AIH and PBC 2016", Hepatol Int, 10, pp.909~915 (2016)
12. Cheung KS, "Epidemiology and natural history of primary biliary cholangitis in the Chinese: a territory-based study in Hong Kong between 2000 and 2015", Clin Transl Gastroenterol, 8, pp.e116~ (2017)
13. Kim KA, "Populationbased epidemiology of primary biliary cirrhosis in South Korea", Aliment Pharmacol Ther, 43, pp.154~162 (2016)
14. Tanaka A, "Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan", Hepatol Res, 49, pp.881~889 (2019)
15. Sook-Hyang Jeong, "Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea", Clinical and Molecular Hepatology, 24(1), pp.10~19 (2018), 대한간학회
16. Boonstra K, "Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review", J Hepatol, 56, pp.1181~1188 (2012)
17. French J, "Increasing prevalence of primary biliary cholangitis in Victoria, Australia", J Gastroenterol Hepatol, 35, pp.673~679 (2020)
18. Marschall HU, "Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort", Sci Rep, 9, pp.11525~ (2019)
19. Lleo A, "Evolving trends in female to male incidence and male mortality of primary biliary cholangitis", Sci Rep, 6, pp.25906~ (2016)
20. Marzioni M, "Epidemiology of primary biliary cholangitis in Italy: evidence from a realworld database", Dig Liver Dis, 51, pp.724~729 (2019)
21. Neuberger J, "Primary biliary cirrhosis", Gut, (Suppl), pp.S73~S78 (1991)
22. Talwalkar J, "Primary biliary cirrhosis", Lancet, 362, pp.53~61 (2003)
23. Van de Water J, "The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase", J Exp Med, 167, pp.1791~1799 (1988)
24. Oertelt S, "A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis", Hepatology, 45, pp.659~665 (2007)
25. Dubel L, "Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis", Hepatology, 29, pp.1013~1018 (1999)
26. Tanaka A, "The genetics and epigenetics of primary biliary cholangitis", Clin Liver Dis, 22, pp.443~455 (2018)
27. Björkland A, "Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer cells and recruitment of primed memory T cells", Hepatology, 13, pp.1106~1111 (1991)
28. Krams SM, "Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis", Hepatology, 12, pp.306~313 (1990)
29. Imai T, "Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion", Cell, 91, pp.521~530 (1997)
30. Isse K, "Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts", Hepatology, 41, pp.506~516 (2005)
31. Shimoda S, "CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis", Hepatology, 51, pp.567~575 (2010)
32. Harada K, "Clinicopathological significance of serum fractalkine in primary biliary cirrhosis", Dig Dis Sci, 58, pp.3037~3043 (2013)
33. Lleo A, "Apotopes and the biliary specificity of primary biliary cirrhosis", Hepatology, 49, pp.871~879 (2009)
34. Lleo A, "Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis", Hepatology, 52, pp.987~998 (2010)
35. Tanaka A, "The genetics of primary biliary cholangitis", Curr Opin Gastroenterol, 35, pp.93~98 (2019)
36. Örnolfsson KT, "Using the Icelandic genealogical database to define the familial risk of primary biliary cholangitis", Hepatology, 68, pp.166~171 (2018)
37. Cordell HJ, "International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways", Nat Commun, 6, pp.8019~ (2015)
38. Hirschfield GM, "Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis", Nat Genet, 42, pp.655~657 (2010)
39. Hirschfield GM, "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants", N Engl J Med, 360, pp.2544~2555 (2009)
40. Hirschfield GM, "Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes", Genes Immun, 13, pp.328~335 (2012)
41. Juran BD, "Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants", Hum Mol Genet, 21, pp.5209~5221 (2012)
42. Kawashima M, "Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population", Hum Mol Genet, 26, pp.650~659 (2017)
43. Liu JZ, "Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis", Nat Genet, 44, pp.1137~1141 (2012)
44. Liu X, "Genomewide meta-analyses identify three loci associated with primary biliary cirrhosis", Nat Genet, 42, pp.658~660 (2010)
45. Mells GF, "Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis", Nat Genet, 43, pp.329~332 (2011)
46. Nakamura M, "Genome-wide association study identifies TNFSF15and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population", Am J Hum Genet, 91, pp.721~728 (2012)
47. Qiu F, "A genome-wide association study identifies six novel risk loci for primary biliary cholangitis", Nat Commun, 8, pp.14828~ (2017)
48. Dong M, "Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population", Clin Rev Allergy Immunol, 48, pp.316~321 (2015)
49. Burroughs AK, "Bacteriuria and primary biliary cirrhosis", Gut, 25, pp.133~137 (1984)
50. Corpechot C, "Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis", J Hepatol, 53, pp.162~169 (2010)
51. Gershwin ME, "Risk factors and comorbidities in primary biliary cirrhosis:a controlled interview-based study of 1032 patients", Hepatology, 42, pp.1194~1202 (2005)
52. Howel D, "An exploratory population-based case-control study of primary biliary cirrhosis", Hepatology, 31, pp.1055~1060 (2000)
53. Ala A, "Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites", Hepatology, 43, pp.525~531 (2006)
54. Amano K, "xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid", J Immunol, 174, pp.5874~5883 (2005)
55. McNally RJ, "No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England", Am J Epidemiol, 179, pp.492~498 (2014)
56. rince MI, "The geographical distribution of primary biliary cirrhosis in a welldefined cohort", Hepatology, 34, pp.1083~1088 (2001)
57. Rieger R, "Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis", J Autoimmun, 27, pp.7~16 (2006)
58. Tang R, "Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy", Gut, 67, pp.534~541 (2018)
59. Ma HD, "Gut microbiota translocation promotes autoimmune cholangitis", J Autoimmun, 95, pp.47~57 (2018)
60. Ryan PM, "Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions", Diabetol Metab Syndr, 9, pp.102~ (2017)
61. Staley C, "Interaction of gut microbiota with bile acid metabolism and its influence on disease states", Appl Microbiol Biotechnol, 101, pp.47~64 (2017)
62. Hofmann AF, "Bile salts of vertebrates:structural variation and possible evolutionary significance", J Lipid Res, 51, pp.226~246 (2010)
63. Chen ML, "Emerging roles of bile acids in mucosal immunity and inflammation", Mucosal Immunol, 12, pp.851~861 (2019)
64. Yang H, "Bile acids and the potential role in primary biliary cirrhosis", Digestion, 94, pp.145~153 (2016)
65. Li Y, "Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases", Autoimmun Rev, 16, pp.885~896 (2017)
66. Melbye P, "Short-chain fatty acids and gut microbiota in multiple sclerosis", Acta Neurol Scand, 139, pp.208~219 (2019)
67. Jones-Hall YL, "The intersection of TNF, IBD and the microbiome", Gut Microbes, 7, pp.58~62 (2016)
68. Lindor KD, "Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 69, pp.394~419 (2019)
69. Working Subgroup for Clinical Practice Guidelines for Primary Biliary Cirrhosis, "Guidelines for the management of primary biliary cirrhosis: the intractable hepatobiliary disease study group supported by the Ministry of Health, Labour and Welfare of Japan", Hepatol Res, 44(Suppl S1), pp.71~90 (2014)
70. Murillo Perez CF, "Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response", Aliment Pharmacol Ther, 50, pp.1127~1136 (2019)
71. Joshi S, "Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis?", Am J Gastroenterol, 97, pp.999~1002 (2002)
72. Mattalia A, "Characterization of antimitochondrial antibodies in health adults", Hepatology, 27, pp.656~661 (1998)
73. Shibata M, "Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture", J Gastroenterol, 39, pp.255~259 (2004)
74. Dahlqvist G, "Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis", Hepatology, 65, pp.152~163 (2017)
75. Sun C, "Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: is alkaline phosphatase truly a surrogate marker?", J Autoimmun, 99, pp.33~38 (2019)
76. Liu H, "screen: an IgG", IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis, 2010, pp.35, 436~442
77. Shimoda S, "Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis", Gastroenterology, 124, pp.1915~1925 (2003)
78. Nakamura M, "Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis", Hepatology, 45, pp.118~127 (2007)
79. Scheuer P, "Primary biliary cirrhosis", Proc R Soc Med, 60, pp.1257~1260 (1967)
80. Ludwig J, "Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)", Virchows Arch A Pathol Anat Histol, 379, pp.103~112 (1978)
81. Nakanuma Y, "Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement", Pathol Int, 60, pp.167~174 (2010)
82. Harada K, "Application and validation of a new histologic staging and grading system for primary biliary cirrhosis", J Clin Gastroenterol, 47, pp.174~181 (2013)
83. Poupon R, "Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?", Lancet, 1, pp.834~836 (1987)
84. Lindor KD, "Primary biliary cirrhosis", Hepatology, 50, pp.291~308 (2009)
85. Harms MH, "Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis", J Hepatol, 71, pp.357~365 (2019)
86. Azemoto N, "Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis", J Gastroenterol, 44, pp.630~634 (2009)
87. Carbone M, "The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis", Hepatology, 63, pp.930~950 (2016)
88. Corpechot C, "Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis", Hepatology, 48, pp.871~877 (2008)
89. Corpechot C, "Early primary biliary cirrhosis: biochemical response to treatment and prediction of longterm outcome", J Hepatol, 55, pp.1361~1367 (2011)
90. Kuiper EM, "Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid", Gastroenterology, 136, pp.1281~1287 (2009)
91. Kumagi T, "Baseline ductopenia and treatment response predict longterm histological progression in primary biliary cirrhosis", Am J Gastroenterol, 105, pp.2186~2194 (2010)
92. Lammers WJ, "Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy", Gastroenterology, 149, pp.1804~1812.e4 (2015)
93. Lammers WJ, "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study", Gastroenterology, 147, pp.1338~1349.e5 (2014)
94. Momah N, "Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis", Liver Int, 32, pp.790~795 (2012)
95. Parés A, "Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid", Gastroenterology, 130, pp.715~720 (2006)
96. Carbone M, "Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA response score", Lancet Gastroenterol Hepatol, 3, pp.626~634 (2018)
97. Yagi M, "A validation study of the ursodeoxycholic acid response score in Japanese patients with primary biliary cholangitis", Liver Int, 40, pp.1926~1933 (2020)
98. Nevens F, "A placebo-controlled trial of obeticholic acid in primary biliary cholangitis", N Engl J Med, 375, pp.631~643 (2016)
99. Samur S, "Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis", Hepatology, 65, pp.920~928 (2017)
100. Trauner M, "Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study", Lancet Gastroenterol Hepatol, 4, pp.445~453 (2019)
101. Bowlus CL, "Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis", Clin Gastroenterol Hepatol, 18, pp.1170~1178.e6 (2020)
102. Honda A, "Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid", Hepatology, 57, pp.1931~1941 (2013)
103. Iwasaki S, "Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis", Hepatology Research, 16, pp.12~18 (1999)
104. Corpechot C, "A placebo-controlled trial of bezafibrate in primary biliary cholangitis", N Engl J Med, 378, pp.2171~2181 (2018)
105. Honda A, "Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis", Hepatology, 70, pp.2035~2046 (2019)
106. Bolier R, "Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial", Trials, 18, pp.230~ (2017)
107. Cheung AC, "Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes", Aliment Pharmacol Ther, 43, pp.283~293 (2016)
108. Dohmen K, "Fenofibrate for patients with asymptomatic primary biliary cirrhosis", World J Gastroenterol, 10, pp.894~898 (2004)
109. Hegade VS, "Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score", Dig Dis Sci, 61, pp.3037~3044 (2016)
110. Harms MH, "Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades", Aliment Pharmacol Ther, 49, pp.285~295 (2019)
111. Adam R, "Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)", J Hepatol, 57, pp.675~688 (2012)
112. Singal AK, "Evolving frequency and outcomes of liver transplantation based on etiology of liver disease", Transplantation, 95, pp.755~760 (2013)
113. The Japanese Liver Transplantation Society, "Liver transplantation in Japan. -Registry by the Japanese Liver Transplantation Society-", Jpn J Transplant, 52, pp.134~147 (2015)
114. Bhanji RA, "Montano-Loza AJ. Liver transplantation for overlap syndromes of autoimmune liver diseases", Liver Int, 33, pp.210~219 (2013)
115. Carbone M, "Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation", Am J Transplant, 13, pp.1110~1111 (2013)
116. Charatcharoenwitthaya P, "Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation", Liver Transpl, 13, pp.1236~1245 (2007)
117. Egawa H, "Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis: a Japanese multicenter study", Am J Transplant, 16, pp.1248~1257 (2016)
118. Guy JE, "Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant", Liver Transpl, 11, pp.1252~1257 (2005)
119. Hytiroglou P, "Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: a blind histologic study", Hepatol Res, 39, pp.577~584 (2009)
120. Jacob DA, "Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients", Clin Transplant, 20, pp.211~220 (2006)
121. Khettry U, "Liver transplantation for primary biliary cirrhosis: a long-term pathologic study", Liver Transpl, 9, pp.87~96 (2003)
122. Kogiso T, "Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: a Japanese multicenter retrospective study", Hepatol Commun, 1, pp.394~405 (2017)
123. Liermann Garcia RF, "Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center", Hepatology, 33, pp.22~27 (2001)
124. Manousou P, "Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity", Liver Transpl, 16, pp.64~73 (2010)
125. Montano-Loza AJ, "Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival", Gastroenterology, 156, pp.96~107.e1 (2019)
126. Montano-Loza AJ, "Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation", Am J Transplant, 10, pp.852~858 (2010)
127. Neuberger J, "Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation", Liver Transpl, 10, pp.488~491 (2004)
128. Sanchez EQ, "The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation", Transplantation, 76, pp.1583~1588 (2003)
129. Sylvestre PB, "Recurrence of primary biliary cirrhosis after liver transplantation:histologic estimate of incidence and natural history", Liver Transpl, 9, pp.1086~1093 (2003)
130. Bosch A, "Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence", J Hepatol, 63, pp.1449~1458 (2015)
131. Jacoby A, "Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis", Gut, 54, pp.1622~1629 (2005)
132. Huet PM, "mpact of fatigue on the quality of life of patients with primary biliary cirrhosis", Am J Gastroenterol, 95, pp.760~767 (2000)
133. Mells GF, "Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study", Hepatology, 58, pp.273~283 (2013)
134. Prince M, "Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years", Gastroenterology, 123, pp.1044~1051 (2002)
135. Jopson L, "Fatigue in primary biliary cirrhosis: prevalence, pathogenesis and management", Dig Dis, 33(Suppl 2), pp.109~114 (2015)
136. Carbone M, "Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid", Gastroenterology, 144, pp.560~569.e7 (2013)
137. Grover VP, "Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging", Aliment Pharmacol Ther, 44, pp.936~945 (2016)
138. Lee JY, "Treatment of fatigue in primary biliary cholangitis: a systematic review and meta-analysis", Dig Dis Sci, 64, pp.2338~2350 (2019)
139. Carbone M, "The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study", J Hepatol, 59, pp.490~494 (2013)
140. Silveira MG, "A randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis", Am J Ther, 24, pp.e167~e176 (2017)
141. Beuers U, "Pruritus in cholestasis:facts and fiction", Hepatology, 60, pp.399~407 (2014)
142. Kremer AE, "Lysophosphatidic acid is a potential mediator of cholestatic pru", Gastroenterology, 139, pp.1008~1018.e1 (2010)
143. Kremer AE, "Autotaxin but not bile salts correlate with itch intensity in cholestasis", J Hepatol, 52, pp.S1~ (2010)
144. Kremer AE, "Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions", Hepatology, 56, pp.1391~1400 (2012)
145. Tandon P, "The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus", Am J Gastroenterol, 102, pp.1528~1536 (2007)
146. European Association for the Study of the Liver, "EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis", J Hepatol, 67, pp.145~172 (2017)
147. Yagi M, "Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study", J Gastroenterol, 53, pp.1151~1158 (2018)
148. Hegade VS, "Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a doubleblind, randomised, placebo-controlled, crossover, phase 2a study", Lancet, 389, pp.1114~1123 (2017)
149. Mayo MJ, "A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis", Hepatol Commun, 3, pp.365~381 (2019)
150. Floreani A, "Extrahepatic autoimmune conditions associated with primary biliary cirrhosis", Clin Rev Allergy Immunol, 48, pp.192~197 (2015)
151. Guañabens N, "Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis", Gastroenterology, 138, pp.2348~2356 (2010)
152. Guañabens N, "Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis", J Hepatol, 42, pp.573~577 (2005)
153. Guañabens N, "Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis", Hepatology, 58, pp.2070~2078 (2013)
154. Arase Y, "Efficacy and safety of 3-year denosumab therapy for osteoporosis in patients with autoimmune liver diseases", Hepatology, 71, pp.757~759 (2020)
155. Lleo A, "Quantitation of the rank-rankl axis in primary biliary cholangitis", PLoS One, 11, pp.e0159612~ (2016)
156. Sorokin A, "Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review", Atherosclerosis, 194, pp.293~299 (2007)
157. Floreani A, "Metabolic syndrome associated with primary biliary cirrhosis", J Clin Gastroenterol, 49, pp.57~60 (2015)
158. Cavazza A, "Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers", Hepatology, 50, pp.1162~1168 (2009)
159. Harada K, "Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan", Hepatology, 57, pp.1942~1949 (2013)
160. Trivedi PJ, "Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study", Gut, 65, pp.321~329 (2016)
161. Rong G, "Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis", Clin Rev Allergy Immunol, 48, pp.132~141 (2015)
162. Imam MH, "Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma", Clin Gastroenterol Hepatol, 10, pp.182~185 (2012)
163. Ellinghaus D, "Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4", Hepatology, 58, pp.1074~1083 (2013)
164. Ellinghaus D, "Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci", Nat Genet, 48, pp.510~518 (2016)
165. Folseraas T, "Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci", J Hepatol, 57, pp.366~375 (2012)
166. Ji SG, "Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease", Nat Genet, 49, pp.269~273 (2017)
167. Karlsen TH, "Genome-wide association analysis in primary sclerosing cholangitis", Gastroenterology, 138, pp.1102~1111 (2010)
168. Liu JZ, "Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis", Nat Genet, 45, pp.670~675 (2013)
169. Melum E, "Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci", Nat Genet, 43, pp.17~19 (2011)
170. Srivastava B, "Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis", Scand J Gastroenterol, 47, pp.820~826 (2012)
171. Harada K, "Prevalence and risk factors of hepatocellular carcinoma in Japanese patients with primary biliary cirrhosis", Hepatol Res, 44, pp.133~140 (2014)

관련 논문AI추천